Pharmacokinetics and Safety of a Novel Oral Liquid Formulation of 13-<i>cis</i> Retinoic Acid in Children with Neuroblastoma: A Randomized Crossover Clinical Trial

Pharmacokinetics and Safety of a Novel Oral Liquid Formulation of 13-<i>cis</i> Retinoic Acid in Children with Neuroblastoma: A Randomized Crossover Clinical Trial

(1) Background: 13-<i>cis</i>-retinoic acid (13-CRA) is a key component of neuroblastoma treatment protocols. This randomized crossover study compares the pharmacokinetics (PK), safety and palatability of a novel oral liquid formulation to the current method of extracting 13-CRA from cap...

Full description

Bibliographic Details
Main Authors: Gareth J. Veal, Deborah A. Tweddle, Johannes Visser, Julie Errington, Helen Buck, Josephine Marange, Jon Moss, Shiju Joseph, Hussain Mulla
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Cancers
Subjects:
neuroblastoma
13-CRA
pharmacokinetics
liquid
Online Access:https://www.mdpi.com/2072-6694/13/8/1868

Internet

https://www.mdpi.com/2072-6694/13/8/1868

Similar Items